HCV Core NS3

Hepatitis C Virus Nucleocapsid (core) NS3 Recombinant
Cat. No.
BT12589
Source
Escherichia Coli.
Synonyms
Appearance
Sterile filtered colorless solution.
Purity
Greater than 95.0% as determined by SDS-PAGE.
Usage
THE BioTek's products are furnished for LABORATORY RESEARCH USE ONLY. The product may not be used as drugs, agricultural or pesticidal products, food additives or household chemicals.
Shipped with Ice Packs
In Stock

Description

Recombinant HCV protein produced in E.Coli containing the Core (130 a.a.) and NS3 (236 a.a.) excluding NS4 and NS5 domains having a total Mw of 45kDa and purified by proprietary chromatographic techniques.

Product Specs

Introduction
HCV, a member of the Flaviviridae family, is a small (50nm), enveloped virus containing a single-stranded, positive-sense RNA genome. Characterized by a high replication rate, HCV produces roughly one trillion particles daily within an infected individual. Its RNA polymerase lacks proofreading ability, resulting in a high mutation rate, which is thought to contribute to its ability to evade the host's immune response. HCV is classified into six genotypes (1-6), each with multiple subtypes. The distribution and prevalence of these genotypes vary globally. Genotype is a clinically significant factor influencing the potential response to interferon-based therapy and the required treatment duration. Genotypes 1 and 4 exhibit lower responsiveness to interferon-based treatments compared to genotypes 2, 3, 5, and 6.
Description
This product consists of a recombinant HCV protein produced in E. coli. The protein encompasses the Core (130 amino acids) and NS3 (236 amino acids) regions, excluding the NS4 and NS5 domains, resulting in a total molecular weight of 45kDa. The protein has been purified using proprietary chromatographic techniques.
Physical Appearance
The product appears as a clear, colorless solution that has been sterilized through filtration.
Formulation
The product is provided as a sterile-filtered solution containing phosphate-buffered saline (PBS), 1M urea, and 25mM arginine.
Purity
The purity of the product exceeds 95.0%, as determined by SDS-PAGE analysis.
Stability
For short-term storage (2-4 weeks), the product should be kept at 4°C. For extended storage, it is recommended to freeze the product at -20°C. The addition of a carrier protein (0.1% HSA or BSA) is advised for long-term storage. Repeated freeze-thaw cycles should be avoided.
Source
Escherichia Coli.

Product Science Overview

Introduction

Hepatitis C virus (HCV) is a significant global health concern, affecting millions of people worldwide. It is a member of the Hepacivirus genus within the Flaviviridae family. The HCV genome is a single-stranded positive-sense RNA of approximately 9.6 kb in length, encoding a single polyprotein that is processed into structural and non-structural proteins .

Structure and Function of HCV Proteins

The HCV polyprotein is co- and post-translationally processed by cellular and viral proteases to yield 11 viral proteins. These include three structural proteins (core, E1, and E2), a small polypeptide named p7, and six non-structural (NS) proteins (NS2, NS3, NS4A, NS4B, NS5A, and NS5B) .

  • Core Protein: The core protein forms the nucleocapsid, which encapsulates the viral RNA. It plays a crucial role in the assembly and release of the virus.
  • NS3 Protein: The NS3 protein is a multifunctional enzyme with serine protease and helicase activities. It is responsible for cleaving the viral polyprotein to release non-structural proteins and plays a role in subverting the host immune response .
Recombinant NS3 Protein

Recombinant NS3 protein is produced using various expression systems, such as E. coli, to study its structure and function. The NS3 protein is crucial for viral replication and pathogenesis, making it a target for antiviral drug development .

Immunogenicity and Vaccine Development

The core and NS3 proteins are major immunogenic proteins in HCV infection. They elicit strong humoral and cellular immune responses, making them potential candidates for vaccine development . Various strategies, such as incorporating multiple viral proteins and molecular tags, have been employed to optimize the efficacy of HCV DNA vaccines .

Quick Inquiry

Personal Email Detected
Please use an institutional or corporate email address for inquiries. Personal email accounts ( such as Gmail, Yahoo, and Outlook) are not accepted. *
© Copyright 2024 Thebiotek. All Rights Reserved.